Johnson & Johnson Income from Continuous Operations 2010-2024 | JNJ

Johnson & Johnson annual/quarterly income from continuous operations history and growth rate from 2010 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
  • Johnson & Johnson income from continuous operations for the quarter ending September 30, 2024 was $2.694B, a 37.48% decline year-over-year.
  • Johnson & Johnson income from continuous operations for the twelve months ending September 30, 2024 was $14.767B, a 30.79% increase year-over-year.
  • Johnson & Johnson annual income from continuous operations for 2023 was $13.326B, a 18.59% decline from 2022.
  • Johnson & Johnson annual income from continuous operations for 2022 was $16.37B, a 8.04% decline from 2021.
  • Johnson & Johnson annual income from continuous operations for 2021 was $17.801B, a 20.98% increase from 2020.
Johnson & Johnson Annual Income from Continuous Operations
(Millions of US $)
2023 $13,326
2022 $16,370
2021 $17,801
2020 $14,714
2019 $15,119
2018 $15,297
2017 $1,300
2016 $16,540
2015 $15,409
2014 $16,323
2013 $13,831
2012 $10,514
2011 $9,672
2010 $13,334
2009 $12,266
Johnson & Johnson Quarterly Income from Continuous Operations
(Millions of US $)
2024-09-30 $2,694
2024-06-30 $4,686
2024-03-31 $3,255
2023-12-31 $4,132
2023-09-30 $4,309
2023-06-30 $5,376
2023-03-31 $-491
2022-12-31 $2,097
2022-09-30 $4,310
2022-06-30 $4,814
2022-03-31 $5,149
2021-12-31 $1,659
2021-09-30 $3,667
2021-06-30 $6,278
2021-03-31 $6,197
2020-12-31 $1,738
2020-09-30 $3,554
2020-06-30 $3,626
2020-03-31 $5,796
2019-12-31 $4,010
2019-09-30 $1,753
2019-06-30 $5,607
2019-03-31 $3,749
2018-12-31 $3,042
2018-09-30 $3,934
2018-06-30 $3,954
2018-03-31 $4,367
2017-12-31 $-10,713
2017-09-30 $3,764
2017-06-30 $3,827
2017-03-31 $4,422
2016-12-31 $3,814
2016-09-30 $4,272
2016-06-30 $3,997
2016-03-31 $4,457
2015-12-31 $3,215
2015-09-30 $3,358
2015-06-30 $4,516
2015-03-31 $4,320
2014-12-31 $2,521
2014-09-30 $4,749
2014-06-30 $4,326
2014-03-31 $4,727
2013-12-31 $3,519
2013-09-30 $2,982
2013-06-30 $3,833
2013-03-31 $3,497
2012-12-31 $2,567
2012-09-30 $2,629
2012-06-30 $1,408
2012-03-31 $3,910
2011-12-31 $218
2011-09-30 $3,202
2011-06-30 $2,776
2011-03-31 $3,476
2010-12-31 $1,942
2010-09-30 $3,417
2010-06-30 $3,449
2010-03-31 $4,526
2009-12-31 $2,206
2009-09-30 $3,345
2009-06-30 $3,208
2009-03-31 $3,507
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $368.366B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94